Company / SG&A Expense
Vaxcyte, Inc. SG&A Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$129.4M
FY2025
5-year range
$25.3M / $129.4M
FY2021-FY2025
Trend
+39.3%
vs FY2024
Sector context
#100 of 213
Health Care
What the data says
At $129M, Vaxcyte, Inc.'s sg&a expense ranks #114 of 213 in the Health Care sector. SG&A Expense has increased for 7 consecutive years, from $5M in FY2018 to $129M in FY2025.
Based on SEC 10-K filings.
$129M in FY2025 with a 5-year CAGR of +51.9%.
Increased from $61M to $129M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +48.1%
- 5-Year CAGR
- +51.9%
- 10-Year CAGR
- -
Sector benchmark
#114 of 213 in Health CareTop 53% of 213This company $129.4M Sector average $722.3M
▼
-82.1% below sector average
Key checks
Key Insights
- Vaxcyte, Inc.'s sg&a expense has grown for 7 consecutive years.
- 5-year CAGR of +51.9%, indicating consistent growth.
- In FY2025, sg&a expense increased 39.3% year-over-year.
- Ranks #100 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $129.4M | +39.3% |
| FY2024 | $92.9M | +53.1% |
| FY2023 | $60.7M | +52.5% |
| FY2022 | $39.8M | +57.6% |
| FY2021 | $25.3M | +57.7% |
| FY2020 | $16.0M | +87.4% |
| FY2019 | $8.5M | +58.6% |
| FY2018 | $5.4M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026